Quantcast
Last updated on April 16, 2014 at 13:25 EDT

Latest Tumor necrosis factor-alpha Stories

2013-11-14 12:26:27

Compared to One Year Ago, TNF-alpha Inhibitors Have Seen Growth in All Three Lines of Therapy, According to a New Report from Decision Resources BURLINGTON, Mass., Nov. 14, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that through examination of U.S. patient-level claims data, the TNF-alpha inhibitors drug class has seen growth in all three lines of therapy, particularly the second- and...

2013-10-23 23:32:32

The process involves a novel physical therapy utilizing stretching, massage and strength training coupled with a neuro anti-inflammatory agent. Reductions in spasticity and recovery of feeling are generally observed on the first day and continue to build with continued treatment according to Neurological Wellness Center physicians. (PRWEB) October 23, 2013 Phillip Koss, owner of http://www.strechforlife.com/ is quick to point out that this process is no panacea. A severely disabled...

2013-10-21 12:24:34

Efficacious Emerging Biologics and Entry of Oral Agents Will Increase Competition in the TNF-Alpha-Refractory Space, According to a New Report from Decision Resources BURLINGTON, Mass., Oct. 21, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the psoriasis drug market will experience substantial growth over the next decade as sales increase from $5.5 billion in 2012 to nearly $9.2...

2013-10-18 08:24:23

Approval represents the fourth U.S. indication for Cimzia® ATLANTA, Oct. 18, 2013 /PRNewswire/ -- regulated information - UCB announced today that the U.S. Food and Drug Administration (FDA) has approved Cimzia(®) (certolizumab pegol) for the treatment of adults with active ankylosing spondylitis (AS). The FDA also issued a Complete Response Letter relating to the supplemental Biologics License Application (sBLA) of Cimzia(®) for the treatment of adults with active axial spondyloarthritis...

2013-10-10 08:26:50

Oral Agents Could Alter the Treatment Algorithm, After Establishing Clinical Profiles at Least Comparable to TNF-alpha Inhibitors, According to a New Report from Decision Resources BURLINGTON, Mass., Oct. 10, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the rheumatoid arthritis drug market will experience moderate growth over the next decade as sales increase from $12.3 billion in...

2013-10-09 12:26:03

Key Drivers of Market Growth Will Be the Uptake of Humira, Simponi, Vedolizumab and Tofacitinib, According to Findings from Decision Resources BURLINGTON, Mass., Oct. 9, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the ulcerative colitis drug market will increase from $2.1 billion in 2012 to $3.6 billion in 2022 in the United States, France, Germany, Italy, Spain, the...

2013-08-08 23:17:34

MD Biosciences focuses on rapid and cost effective models of psoriasis involving the IL-23/Th17 axis in order to provide companies alternatives to complex and cost prohibitive xenotransplantation models for screening. With the earlier launch of the IMQ model and now the IL-23 psoriasis model, MD Biosciences offers a range of rapid models for dermal conditions such as dermatitis and psoriasis. St Paul, MN (PRWEB) August 08, 2013 Recent psoriasis research has focused extensively on the...

2013-07-23 11:45:23

A gene long presumed dead comes to life under the full moon of inflammation, Stanford University School of Medicine scientists have found. The discovery, described in a study to be published July 23 in eLife, may help explain how anti-inflammatory steroid drugs work. It also could someday lead to entirely new classes of anti-inflammatory treatments without some of steroids' damaging side effects. Chronic inflammation plays a role in cancer and in autoimmune, cardiovascular and...

2013-06-27 08:30:51

Surveyed U.S. Payers Are Particularly Receptive to New Therapies That Offer Improved Effect on Induction and Maintenance of Remission Over Currently Available Agents, According to a New Report from Decision Resources BURLINGTON, Mass., June 27, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a therapy that enables a greater percentage of patients to maintain remission is one of the...

2013-06-03 08:25:49

Efficacy Advantages of TNF-Alpha Inhibitors Will Likely Constrain Uptake of Emerging Therapies, According to a New Report from Decision Resources BURLINGTON, Mass., June 3, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that based on clinical data and the opinions of interviewed thought leaders, AbbVie/Eisai's Humira has the strongest clinical profile among key marketed products that...